Pleurotus citrinopileatusポリサッカリドは,NF-κB経路による腸壁と炎症調節を改善することによって,DSS誘発性潰瘍性大腸炎を緩和する
Chao Li1, Lu Zhao2, Shichao Yu2
1Department of Neurology, Stroke Center, The First Hospital of Jilin University, Changchun, 130021, China.
International journal of biological macromolecules
|September 6, 2025
まとめ
Pleurotus citrinopileatusからの新しい多糖質CP-2-2は,潰瘍性大腸炎 (UC) に対して重要な治療の可能性を示しています. NF- kB経路を阻害することで炎症を和らげ,腸壁を保護します.
科学分野:
- 薬理学について
- 自然製品化学
- 免疫学
背景:
- 潰瘍性大腸炎 (UC) は慢性炎症性腸疾患で,治療の選択肢は限られている.
- 自然化合物は,免疫調節および抗炎症性のためにますます調査されています.
研究 の 目的:
- デクストラン硫酸ナトリウム (DSS) 誘発性潰瘍性大腸炎に Pleurotus citrinopileatus から分離されたポリサッカリドの薬理学的効果を調査する.
- 単離されたポリサッカリドの作用の仕組みを明らかにする.
主な方法:
- ポリサッカリドCP-2-2をクロマトグラフィック技術を用いて Pleurotus citrinopileatusから分離および浄化.
- CP-2-2の組成,分子量,および構造的特徴 (FTIR,メチル化) の特徴づけ
- 治療効果を評価するためにDSS誘発UCマウスモデルを用いたin vivo試験,細胞メカニズムを調査するためにin vitro試験.
主要な成果:
- 体重減少,疾患活動指数 (DAI),結腸長さの増加など,マウスのUC症状を著しく軽減した.
- CP- 2-2は炎症を誘発するサイトカインの生成を抑制し,NF- kB信号伝達経路を調節した.
- CP- 2 - 2による治療は,腸の病理的損傷を緩和し,腸の障壁機能を改善し,アポトーシスとフェロプトーシスをインビトロで抑制しました.
結論:
- Pleurotus citrinopileatusからの多糖質CP-2-2は,DSS誘発性大腸炎に対する重要な保護効果を示しています.
- 治療の可能性は部分的にNF- kB信号伝達の抑制と腸内皮質細胞の保護に起因する.
- CP-2-2は潰瘍性大腸炎の管理に有望な機能的薬剤です.
関連する概念動画
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
518
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
518
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
680
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
680
Drugs for Treatment of Ulcerative Colitis in IBD
236
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
236
Drugs for Treatment of Diarrhea-Predominant IBS
289
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
289
Chronic Bowel Disorders: Introduction
536
Chronic bowel diseases are a group of long-term conditions affecting the digestive tract, characterized by inflammation and damage to the gut lining. These conditions primarily include irritable bowel syndrome and inflammatory bowel disease.
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
Irritable Bowel Syndrome (IBS) is a common disorder affecting the gastrointestinal tract. The distinctive feature is recurrent abdominal pain associated with altered bowel movements, manifesting as constipation, diarrhea, or fluctuating between both. The...
536
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
407
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
407


